Norfloxacin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Norfloxacin: From Urinary Tract Infections to Hyperamylasemia
One-Sentence Summary
Norfloxacin is a fluoroquinolone antibacterial, noted in the evidence pack as being used mainly for urinary tract infections. The TxGNN model’s top-ranked prediction is Hyperamylasemia, but this is supported by 0 clinical trials and 0 publications, and the evidence pack’s own mechanistic review concludes there is no plausible pharmacological link between the two.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not confirmed via UK licensing data (product holds no UK marketing authorisation); described in the evidence pack’s drug-class notes as mainly used for urinary tract infections |
| Predicted New Indication | Hyperamylasemia |
| TxGNN Prediction Score | 99.70% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for norfloxacin in this evidence pack (flagged as a High-severity data gap, DG002). What can be established from the pack is that norfloxacin is a fluoroquinolone antibacterial that inhibits bacterial DNA gyrase/topoisomerase IV, and that it is mainly used clinically for urinary tract infections.
For the top-ranked prediction — hyperamylasemia — the evidence pack’s own assessment is explicit and should be taken at face value: there is no known pharmacological relationship between norfloxacin’s antibacterial mechanism and pancreatic amylase metabolism, and no clinical trials or literature exist to support this link. This appears to be a high-scoring TxGNN output without independent validation, i.e. a candidate that should not be advanced on current evidence.
Of the ten indications the model surfaced for this drug (see below), only one — septicemic plague (rank 10) — has any biological plausibility, based on a fluoroquinolone class effect (ciprofloxacin, levofloxacin and moxifloxacin are FDA-approved for plague). Norfloxacin itself, however, lacks drug-specific human clinical evidence for this use, owing to its comparatively low tissue penetration and systemic bioavailability.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for hyperamylasemia.
Other Model-Predicted Indications Considered
For transparency, all ten TxGNN-ranked candidates for norfloxacin from this evidence pack are summarised below, as none reached a “Go” recommendation.
| Rank | Predicted Indication | Score | Evidence Level | Decision | Assessment |
|---|---|---|---|---|---|
| 1 | Hyperamylasemia | 99.70% | L5 | Hold | No mechanism, no evidence; likely model noise |
| 2 | Polyclonal hyperviscosity syndrome | 99.70% | L5 | Hold | No mechanism, no evidence |
| 3 | Congenital analbuminemia | 99.67% | L5 | Hold | Hereditary hepatic disorder, unrelated to MOA |
| 4 | Blood group incompatibility | 99.55% | L5 | Hold | Immunohaematological, unrelated to MOA |
| 5 | Punctate epithelial keratoconjunctivitis | 99.54% | L4 | Hold | Literature concerns microsporidial (parasitic), not bacterial, infection — likely name-matching artefact |
| 6 | Premalignant hematological system disease | 99.48% | L5 | Hold | Diagnosis too vague to assess; no evidence |
| 7 | Diffuse scleroderma | 99.44% | L5 | Hold | Autoimmune fibrotic disease, no mechanistic overlap |
| 8 | Monoclonal gammopathy | 99.42% | L5 | Hold | Only related literature concerns antibiotic-resistance side effects, not treatment efficacy |
| 9 | Haematological disease with acquired peripheral neuropathy | 99.38% | L5 | Hold | Fluoroquinolone peripheral neuropathy is a safety signal (FDA boxed warning), not a therapeutic indication |
| 10 | Septicemic plague | 99.37% | L4 | Research Question | Class-effect plausibility (DNA gyrase inhibition vs. Yersinia pestis); no norfloxacin-specific human evidence |
Recommendation: none of these candidates meet the threshold to proceed as a repurposing programme. Rank 10 (septicemic plague) may warrant a research question / literature deep-dive on comparative fluoroquinolone pharmacokinetics, but this is a mechanistic hypothesis, not a treatment recommendation.
UK Market Information
Norfloxacin is not currently marketed in the UK — the evidence pack records 0 marketing authorisations and no licence entries. There is therefore no UK-approved indication text available to reference.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: this evidence pack flags TFDA/MHRA product warnings and contraindications as a Blocking data gap — DG001 — meaning a formal safety pre-assessment (S1) cannot proceed until official product labelling is retrieved.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (hyperamylasemia) has no supporting clinical trials, no supporting literature, and no plausible mechanistic link per the evidence pack’s own review — it is best treated as an unvalidated model output. None of the other nine candidates fare better, and the drug itself is unlicensed in the UK with no available mechanism-of-action or safety data.
To proceed, the following is needed:
- Product labelling / warnings and contraindications (Blocking gap — source: official regulator PDF)
- Mechanism of action data (High-severity gap — source: DrugBank API)
- Independent literature or preclinical validation specifically linking norfloxacin to any of the ten predicted indications
- If pursuing the plague hypothesis (rank 10), comparative pharmacokinetic data versus approved fluoroquinolones (ciprofloxacin, levofloxacin)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.